Current Edition


As end of New York opioid trial nears, AbbVie’s Allergan ponies up $200M to settle its part of the case

On the day of closing arguments in a high-profile New York opioid trial, AbbVie has inked a $200 million settlement to put the case to …

Continue Reading →

Crippled by opioid-crisis litigation, Mallinckrodt settlement brings company closer to reorganisation

This has been a summer of reckoning for many companies that aggressively marketed opioids while downplaying their addictive power. For Mallinckrodt, which filed for bankruptcy …

Continue Reading →